ストックスクリーナーアプリを入手
7.31
7.12%
-0.56
前日終値:
$7.87
開ける：
$7.28
24時間の取引高:
109.62K
Relative Volume:
11.46
時価総額：
$187.30K
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-95.98%
1か月 パフォーマンス:
-96.90%
6か月 パフォーマンス:
-99.68%
1年 パフォーマンス:
-99.95%
1日の値動き範囲:
$6.71
$7.97
1週間の範囲:
$6.71
$164.00
52週間の値動き範囲:
$6.71
$17,908.00
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
名前
Cero Therapeutics Holdings Inc
セクター
電話
650-407-2376
住所
201 HASKINS WAY, SOUTH SAN FRANCISCO
CERO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CERO
Cero Therapeutics Holdings Inc
|
7.31 | 187.30K | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Cero Therapeutics Holdings Inc (CERO) 最新ニュース
CERo Therapeutics Conducts Reverse Stock Split to Meet Nasdaq Requirements - TipRanks
CERo Therapeutics announces 1-for-20 reverse stock split effective June 13 - MSN
Trading Halted for CERO; Anticipated Announcement Pending | CERO Stock News - GuruFocus
Cero Therapeutics announces 1-for-20 reverse stock split - Yahoo Finance
CERO Announces One-for-Twenty Reverse Stock Split | CERO Stock N - GuruFocus
CERo Therapeutics to implement 1-for-20 reverse stock split By Investing.com - Investing.com South Africa
CERo Therapeutics to implement 1-for-20 reverse stock split - Investing.com Australia
CERo Therapeutics Announces Reverse Stock Split - TipRanks
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split - GlobeNewswire
CERo Therapeutics Sets Major 1:20 Reverse Split, Shares Consolidate 95% Next Week - Stock Titan
CERo Therapeutics issues additional Series D stock By Investing.com - Investing.com South Africa
CERo Therapeutics Completes Series D Stock Issuance - TipRanks
CERO Expands Series D Preferred Stock Offering to Raise Capital - GuruFocus
CERo Therapeutics issues additional Series D stock - Investing.com
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing - The Manila Times
CERo Therapeutics Holdings, Inc. Issues Additional Series D Preferred Stock Shares to Institutional Investors for Up to $8 Million - Nasdaq
CERo Therapeutics Lands $3M Series D Extension as CAR-T Cancer Trial Shows Promise - Stock Titan
CERo Therapeutics regains Nasdaq compliance - MSN
Cero announces two granted U.S. patents, European patent application allowance - Yahoo Finance
CERo Therapeutics secures key patents for cancer therapy By Investing.com - Investing.com South Africa
CERo Therapeutics Expands Leadership with New Executive Roles - TipRanks
Maxim Group Maintains Buy Rating on CERo Therapeutics (CERO) - Insider Monkey
CERO Therapeutics Expands Patent Portfolio with New U.S. and Eur - GuruFocus
CERo Therapeutics secures key patents for cancer therapy - Investing.com Australia
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236 - The Globe and Mail
CERo Therapeutics Holds 18 Patents and Applications Expanding Immunotherapy Portfolio - Nasdaq
CERo Therapeutics Secures 18 Global Patents for Revolutionary Cancer-Fighting Cell Therapy Technology - Stock Titan
CERo Therapeutics Holdings, Inc. (CERO) Doses First Patient in CER-1236 CAR-T AML Trial - MSN
CERo Therapeutics (NASDAQ:CERO) Rating Lowered to “Hold” at D Boral Capital - Defense World
CERo Therapeutics (NASDAQ:CERO) Receives “Hold” Rating from D. Boral Capital - Defense World
CERo Therapeutics begins phase 1 trial for leukemia treatment By Investing.com - Investing.com South Africa
CERO stock plunges to 52-week low at $0.47 amid market challenges By Investing.com - Investing.com South Africa
CERO Initiates Phase 1 Trial for CER-1236 in Acute Myeloid Leuke - GuruFocus
Cero Therapeutics (CERO) Downgraded to Hold as Stock Faces Another Reverse Split | CERO Stock News - GuruFocus
CERO stock plunges to 52-week low at $0.47 amid market challenges - Investing.com Nigeria
CERo Therapeutics begins phase 1 trial for leukemia treatment - Investing.com
CERO Stock Downgraded to Hold by D. Boral Capital | CERO Stock News - GuruFocus
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial - marketscreener.com
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations - The Manila Times
CERo Therapeutics Holdings, Inc. Doses First Patient with - GlobeNewswire
CERo Therapeutics Announces First Patient Dosed in Phase 1 Trial of CER-1236 for Acute Myeloid Leukemia, to be Featured at ASCO 2025 - Nasdaq
First Patient Receives Revolutionary CAR-T Therapy in Groundbreaking Leukemia Clinical Trial - Stock Titan
Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket - Benzinga
LI Earnings: Li Auto Delivers Q1 Beat but Guidance Disappoints - The Globe and Mail
Meet the Monster Quantum Computing Stock That Continues to Crush the Market - The Globe and Mail
CERo Therapeutics (NASDAQ:CERO) Coverage Initiated by Analysts at Maxim Group - Defense World
Maxim Group Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation - Nasdaq
Maxim Group sets Cero Therapeutics stock with $3 target By Investing.com - Investing.com Nigeria
CERO Therapeutics (CERO) Receives 'Buy' Rating from Maxim Group | CERO Stock News - GuruFocus
Maxim Group sets Cero Therapeutics stock with $3 target - Investing.com
Cero Therapeutics Holdings Inc (CERO) 財務データ
Cero Therapeutics Holdings Inc (CERO) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Cero Therapeutics Holdings Inc (CERO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| YK Bioventures Opportunities G | 10% Owner |
Dec 13 '24 |
Sale |
0.06 |
2,998,908 |
179,934 |
13,005,169 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 12 '24 |
Sale |
0.07 |
1,614,541 |
113,018 |
16,004,077 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 11 '24 |
Sale |
0.08 |
1,343,801 |
107,504 |
17,618,618 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 06 '24 |
Sale |
0.12 |
1,236,874 |
148,425 |
21,383,909 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 10 '24 |
Sale |
0.09 |
1,570,947 |
141,385 |
18,962,419 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 09 '24 |
Sale |
0.11 |
850,543 |
93,560 |
20,533,366 |
| SLOAN STUART M | 10% Owner |
Sep 25 '24 |
Sale |
0.10 |
532,486 |
55,538 |
21,067,956 |
| YK Bioventures Opportunities G | 10% Owner |
Oct 10 '24 |
Sale |
0.10 |
3,250,000 |
325,000 |
22,620,783 |
1.91%
1.17%
大文字化:
|
ボリューム (24 時間):